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Abstract
Background: Diabetes is a major cardiovascular risk factor. However, its influence on the rate of occurrence of
cardiovascular (CV) events during a clinical trial that included a diabetes subgroup has not yet been quantified.
Aims: To establish equations relating baseline diabetes prevalence and incident CV events, based on comparator
arms data of major lipid-modifying trials.
Methods: Meta-analysis of primary outcomes (PO) rates of key prospective trials, for which the baseline proportion
of diabetics was reported, including studies having specifically reported CV outcomes within their diabetic
subgroups.
Results: 47 studies, representing 330,376 patients (among whom 124,115 diabetics), were analyzed as regards the
relationship between CV outcomes rates (including CHD) and the number of diabetics enrolled. Altogether, a total of
18,445 and 16,156 events occurred in the comparator and treatment arms, respectively. There were significant linear
relationships between diabetes prevalence and both PO and CHD rates (%/year): y = 0.0299*x + 3.12 [PO] (p = 0.0128);
and y = 0.0531*x + 1.54 [CHD] (p = 0.0094), baseline diabetes predicting PO rates between 3.12 %/year (no diabetic
included) and 6.11 %/year (all patients diabetic); and CHD rates between 1.54 %/year (no diabetic) and 6.85 %/year
(all patients diabetic). The slopes of the equations did not differ according to whether they were derived from
primary or secondary prevention trials.
Conclusions: Absolute and relative CV risk associated with diabetes at inclusion can be readily predicted using
linear equations relating diabetes prevalence to primary outcomes or CHD rates.
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Introduction
Key prospective trials have demonstrated the effective-
ness of long-term control of conventional risk factors
(RFs) to prevent cardiovascular (CV) events. Next to de-
creasing tobacco use and physical inactivity, indisputable
gains were achieved by targeting hypertension and
hypercholesterolemia. Nevertheless, there remained a
high residual risk of incident CV events in control and
comparator arms of these trials, even in patients receiv-
ing appropriate standard of care [1–4]. This residual risk
is driven by non-modifiable RFs (age; gender; familial or
genetic features; and diabetes) and by modifiable con-
ventional or emerging RFs (eg. atherogenic dyslipidemia;
remnant lipoproteins; hyperglycaemia; hyperinsulinae-
mia; metabolic syndrome; subclinical inflammation; and
chronic kidney disease).
Based on epidemiology and prospective studies, type 2
diabetes mellitus (T2DM) significantly increases the abso-
lute risk of developing coronary heart disease (CHD), and
confers a higher residual risk of large and small vessel dam-
age. In the microcirculation, such risk is directly related to
hyperglycaemia, whereas in large vessels, this residual risk
is linked to hypertension, low-density lipoproteins (LDL);
non-LDL dyslipidemias; and other metabolic comorbidities
[5–10]. As a result, having T2DM, either individually or at
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a sub-group level (within a cohort or population) increases
residual CV risk to an extent that needs to be determined.
Since residual risk varies considerably from one study to
another, such an evaluation would require going beyond
comparing CV outcomes rates in diabetic vs. nondiabetic
subgroups of individual trials.
The aim of this work was to establish equations relat-
ing baseline diabetes prevalence and incident CV events,
based on comparator arms data of major clinical trials
having investigated the potential CV benefit of various
pharmacological or dietary interventions targeting, in
the vast majority, lipids and lipoproteins. We performed
a systematic meta-analysis of CV outcomes rates of
those key prospective studies, for which the baseline
proportion of diabetics was reported and, where avail-
able, studies having reported CV outcomes of diabetic
subgroups [11–90] (Table 1).
Patients and methods
To be selected for inclusion, major clinical trials with
CV outcomes had to meet three requirements: (i) the
main purpose of the trial was to study the effect on
CHD of a pharmacological or dietary intervention tar-
geting lipids or lipoproteins, with CHD rates as sole pri-
mary outcome (PO), or with a major adverse CV event
(MACE) composite PO comprising CHD; (ii) to focus
exclusively on diabetic patients, or (iii) to report data on
a sufficient number of diabetic patients from pre-/post-
hoc analyses of DM subgroups of the main trial. Among
studies conducted non-exclusively in DM patients, eli-
gible trials had to comply with ≥1 of the following cri-
teria: (i) the main trial had a subgroup of patients
already diagnosed with DM at baseline, whose propor-
tion was deemed sufficiently representative (>15 %); or
(ii) the trial enrolled at least 100 DM patients, regardless
of on-study new-onset diabetes.
For each study, the following items were analyzed: CV
risk category at baseline (primary prevention [PP], second-
ary prevention [SP] or mixed [PP-SP]); number of patients
included; number and proportion of patients with DM at
baseline; number of patients in the active or comparator
arms; duration of follow-up; age at inclusion; number of
males; DM type and duration; HbA1c; total cholesterol
(TC); low-density lipoprotein cholesterol (LDL-C); high-
density lipoprotein cholesterol (HDL-C); non-HDL-
cholesterol (non-HDL-C); apolipoprotein B100 (apoB);
triglycerides (TG); type of pharmacological or dietary
intervention; primary trial outcome; CHD outcomes
(see Table 2 for CV outcomes categories); and CV events
number and rates for each trial.
Results are presented as means (±1 standard deviation
(SD)), or as proportions (%), with between-study range
[BSR] described when needed. Linear regression was
computed using the least-squares method. Results were
considered statistically significant or non-significant
(NS) for p <0.05 or p ≥0.05, respectively.
Results
Forty-seven studies were selected based on the criteria
defined above [11–90]. They accounted for a total of
330,376 patients. The median year of publication for all
studies was 2005. Table 1 describes, for each study, the
acronym’s definition; the CV prevention category; the
cohort size and the number or proportion of diabetic at
baseline; the number of patients randomized in the ac-
tive or comparator arms; the follow-up duration; and
publication year. For all studies, mean age (1SD) was
61.7 (6.4) years, and the proportion of males was 74
(17) %. Regarding ethnicity, the majority of patients
studied were Caucasian (median 86.5 % [between-study
range (BSR 0 %)–99.2 %] Three studies [JELIS; MEGA; and
PROFIT-J] included only Japanese patients [59, 66, 74].
Among studies, 8 of 47 (17 %; n = 42,279) enrolled pa-
tients in PP at baseline; 17 of 47 (36 %; n = 131,425) in-
cluded populations whose CV risk was a mix of PP and
SP; and 22 of 47 (47 %; n = 156,672) were SP trials. Lipid
values at baseline were (mg/dL): 209 (34) [TC]; 126 (32)
[LDL-C]; 44 (7) [HDL-C]; 161 (32) [non-HDL-C]; 99
(19) [apoB] and 162 (27) [TG]. In total, these studies
have included 124,115 diabetic patients, representing
42.1 % [BSR 2.3 %–100 %] of the population studied.
For studies that reported diabetes duration, it averaged
7.5 (4.9) years, whereas metabolic control assessed by
HbA1c was 7.49 (0.68) % (Table 3). The trials investi-
gated the following interventions over a mean (1SD)
duration of 4.4 (1.9) years [BSR: 1.0–13.3 years]: statins
(21 trials); fibrates (9 trials); n-3 fatty acids and/or trad-
itional Mediterranean diet (5 trials); niacin (4 trials);
CETP-inhibitor (2 trials); PPAR-γ agonist (2 trials); ezeti-
mibe (1 trial); PPAR-α/γ agonist (1 trial); and Lp-PLA2
inhibitor (1 trial) (Table 4).
For all 47 studies, a total of 18,445 and 16,156 events oc-
curred in the comparator and treatment arms, respectively.
On an annual basis, this was equivalent to an average rate
of occurrence for the primary CV outcome of 3.6 (2.4)
%/year [BSR 0.5–11.8] (comparator) and 3.0 (1.9)%/year
[BSR 0.3–9.1] (treatment), respectively (Table 4). The slopes
of the equations relating PO rates (y) to diabetes prevalence
(x) did not differ according to whether they were derived
from PP or SP trials: thus, for PP trials y = 0.0208* x + 0.53
(R2 = 0.6369; p = 0.0058), whereas y = 0.0267* x +3.76
(R2 = 0.1436; p = 0.0464) for SP trials.
When comparing PO rates from the comparator arms of
studies published prior to 2005 vs. those published ≥2005,
average PO incidence decreased from 3.7 %/year [<2005] to
2.7 %/year [≥2005] for non-diabetic patients, ie. absolute
and relative reductions of 1 % and 28 % (NS). For diabetic
patients, the event rate decreased from 5.0 %/year [<2005]
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Table 1 Overview of 47 landmark prospective clinical trials with CV outcomes having included a substantial number and/or
proportion of diabetic patients at baseline
CV prevention Patients Diabetes Active arm Comparator arm Follow-up Publication year Reference
n n % n n years
4D PP-SP 1255 1255 100 619 636 4.0 2005 [11]
4S SP 4444 202 5 2221 2223 5.4 1994 [12–14]
diabetes substudy SP 202 202 100 105 97 5.4 1997 [14]
ACCORD-Lipid PP-SP 5518 5518 100 2765 2753 4.7 2010 [15, 16]
ADDITION-Europe PP-SP 3055 3055 100 1678 1377 5.3 2011 [17, 18]
AFCAPS/TexCAPS PP 6605 155 2 3304 3301 5.2 1998 [19, 20]
AIM-HIGH SP 3414 1158 34 1718 1696 3.0 2011 [21, 22]
AleCardio SP 7226 7226 100 3616 3610 2.0 2014 [23, 24]
ALERT PP-SP 2102 396 19 1050 1052 5.1 2003 [25]
ALLHAT-LLT PP-SP 10355 3638 35 5170 5185 4.8 2002 [26]
Alpha-Omega SP 4837 1754 36 2404 2433 3.4 2010 [27]
ASCOT-LLA PP 10305 2532 25 5168 5137 3.3 2003 [28, 29]
diabetes substudy PP 2532 2532 100 1258 1274 3.3 2005 [29]
ASPEN PP 2410 2410 100 1211 1199 4.0 2006 [30]
AURORA PP-SP 2773 731 26 1389 1384 3.8 2009 [31, 32]
diabetes substudy PP-SP 731 731 100 388 343 2.8 2011 [32]
BIP SP 3090 309 10 1548 1542 6.2 2000 [33, 34]
CARDS PP 2838 2838 100 1428 1410 3.9 2004 [35]
CARE SP 4159 586 14 2081 2078 5.0 1998 [36–38]
diabetes substudy SP 586 586 100 282 304 5.0 1998 [38]
CDP (clofibrate) SP 3892 1517 39 1103 2789 6.2 1975 [39, 40]
CDP (niacin) SP 3908 1524 39 1119 2789 6.2 1975 [39, 40]
dal-OUTCOMES SP 15871 3882 24 7938 7933 2.6 2012 [41, 42]
DIS PP 761 761 100 379 382 5.0 1991 [43]
FIELD PP-SP 9795 9795 100 4895 4900 5.0 2005 [44–46]
GISSI-Prevenzione SP 4271 582 14 2138 2133 2.0 2000 [47]
GREACE SP 1600 313 20 880 720 3.0 2002 [48, 49]
diabetes substudy SP 313 313 100 161 152 3.0 2003 [49]
HATS SP 107 17 16 73 34 3.0 2001 [50]
HHS PP 4081 108 3 2051 2030 5.0 1987 [51, 52]
diabetes substudy PP 135 135 100 59 76 5.0 1992 [52]
HPS - MRC/BHF PP-SP 20536 5963 29 10269 10267 5.0 2002 [53, 54]
diabetes substudy PP-SP 5963 5963 100 2978 2985 4.8 2003 [54]
HPS2-THRIVE SP 25673 8299 32 12838 12835 3.9 2013 [55]
IDEAL SP 8888 1057 12 4439 4449 4.8 2005 [56, 57]
ILLUMINATE PP-SP 15067 6661 44.2 7533 7534 1.0 2007 [58]
JELIS PP-SP 18645 3040 16.3 9326 9319 4.6 2007 [59]
LEADER PP-SP 1568 268 17 783 785 4.6 2002 [60, 61]
LIPID SP 9014 782 9 4512 4502 6.1 1998 [62–64]
LIPS SP 1677 202 12 844 833 3.9 2002 [65]
MEGA PP 7832 1632 21 3866 3966 5.3 2006 [66]
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to 4.3 %/year [≥2005], ie. absolute and relative reductions of
0.7 % and 14 % (NS).
Among these, 33 trials, totaling 259,151 patients, are
described below as predominantly non-diabetes studies
[12–14, 19–22, 25–29, 31–34, 36–42, 47–66, 68–70, 75,
78–80, 82–90] (Table 1). The mean age was 61.4 (5.5)
years [BSR 47.0–75.0], and the proportion of males was
78.6 (17.8) % [BSR 31.4–100]. Among predominantly
non-diabetes studies, 4 of 33 (12 %) enrolled patients
who were in PP at baseline; 9 of 33 (27 %) included
mixed populations whose CV risk was either PP or SP;
and 20 of 33 (61 %) were clinical trials in SP only. Lipid
values at baseline were (mg/dL): 212 (38) [TC]; 129 (36)
[LDL-C]; 44 (7) [HDL-C]; 165 (36) [non-HDL-C]; 98
(21) [apoB] and 160 (25) [TG]. In total, these studies
have included 63.189 diabetic patients, representing
21.3 % [BSR 2.3 %–44.2 %] of the population studied
(Table 1; Table 3). These predominantly non-diabetes
studies investigated the following interventions over a
mean (1SD) duration of 4.3 (1.5) years [BSR: 1.0–
7.5 years]: statins (19 trials); fibrates (6 trials); n-3 fatty
acids (2 trials); niacin (4 trials); CETP-inhibitor (2 trials);
ezetimibe (1 trial); and Lp-PLA2 inhibitor (1 trial)
(Table 4).
Amongst predominantly non-diabetes studies, we iden-
tified 9 diabetes sub-studies (DSS), numbering 12,732
patients, published as pre-/post-hoc sub-group analyses
of DM patients [14, 29, 32, 38, 49, 52, 54, 86, 90]
(Table 1). The mean age was 60.4 (5.3) years [BSR 49.0–
65.0], and the proportion of males was 74.9 (12.8) %
Table 1 Overview of 47 landmark prospective clinical trials with CV outcomes having included a substantial number and/or
proportion of diabetic patients at baseline (Continued)
ORIGIN PP-SP 12536 11081 88.4 6281 6255 6.2 2012 [67]
PERFORM SP 19120 5299 27.7 9562 9558 2.4 2011 [68]
Post-CABG SP 1351 116 9 676 675 7.5 2000 [69, 70]
PREDIMED PP 7447 3614 49 4997 2450 4.5 2013 [71]
PROACTIVE SP 5238 5238 100 2605 2633 2.9 2005 [72, 73]
PROFIT-J PP-SP 481 481 100 234 247 1.8 2014 [74]
PROSPER PP-SP 5804 623 11 2891 2913 3.2 2002 [75]
RPS PP-SP 12505 7494 60 6239 6266 5.0 2013 [76, 77]
SHARP PP-SP 9270 2094 23 4650 4620 4.9 2011 [78]
STABILITY SP 15828 5351 34 7924 7904 3.7 2014 [79, 80]
STENO-2 PP-SP 160 160 100 80 80 13.3 2008 [81]
TNT SP 10001 1501 15 4995 5006 4.9 2005 [82–86]
diabetes substudy SP 1501 1501 100 753 748 4.9 2006 [86]
VA Cooperative Study SP 532 128 24 268 264 1.8 1973 [87]
VA-HIT SP 2531 769 30 1264 1267 5.1 1999 [88–90]
diabetes substudy SP 769 769 100 377 392 5.1 2002 [90]
Total (n) 330376 124115 165022 165354
Mean 4.4
CV: cardiovascular; PP and SP: primary and secondary prevention. Acronyms: 4D: Die Deutsche Diabetes Dialyse studie; 4S: Scandinavian Simvastatin Survival
Study; ACCORD-Lipid: Action to Control Cardiovascular Risk in Diabetes - Lipid arm; ADDITION-Europe: Anglo-Danish-Dutch Study of Intensive Treatment in People
with Screen Detected Diabetes in Primary Care; AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study; AIM-HIGH: Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes; AleCardio: A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to
Reduce CV Risk in CHD Patients with a Recent ACS and T2DM; ALERT: Assessment of Lescol in Renal Transplantation; ALLHAT-LLT: Antihypertensive and Lipid-Lowering
treatment to prevent Heart Attack Trial; ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm; ASPEN: Atorvastatin as Prevention of CHD
Endpoints in patients with Non-insulin dependent diabetes mellitus; AURORA: A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: an
Assessment of Survival and Cardiovascular Events; BIP: Bezafibrate Infarction Prevention; CARDS: Collaborative Atorvastatin Diabetes Study; CARE : Cholesterol and
Recurrent Events; CDP: Coronary Drug Project; dal-OUTCOMES: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome; DIS: Diabetes Intervention
Study; FIELD: Fenofibrate Intervention and Event Lowering in Diabetes; GISSI-Prevenzione: Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
miocardico - Prevenzione; GREACE: Greek Atorvastatin and Coronary-heart-disease Evaluation; HATS: HDL-Atherosclerosis Treatment Study; HHS: Helsinki
Heart Study; HPS - MRC/BHF: Medical Research Council and British Heart Foundation Heart Protection Study; HPS2-THRIVE: Heart Protection Study - Treatment of HDL to
Reduce the Incidence of Vascular Events; IDEAL: Incremental Decrease in End Points Through Aggressive Lipid Lowering Trial; ILLUMINATE: Investigation of Lipid Level
Management to Understand its Impact in Atherosclerosis Events; JELIS: Japan EPA Lipid Intervention Study; LEADER: Lower Extremity Arterial Disease Event Reduction;
LIPID: Long-term Intervention with Pravastatin in Ischaemic Disease; LIPS: Lescol Intervention Prevention Study; MEGA: Primary Prevention of Cardiovascular Disease with
Pravastatin in Japan; ORIGIN: Outcome Reduction with an Initial Glarigine Intervention; PERFORM: Prevention of cerebrovascular and cardiovascular Events of ischaemic
origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack; Post-CABG (FU): Post Coronary Artery Bypass Graft Trial (follow-up);
PREDIMED: Prevencion con Dieta Mediterranea; PROACTIVE: PROspective pioglitAzone Clinical Trial In macroVascular Events; PROFIT-J: PRimary preventiOn oF hIgh risk
Type 2 diabetes in Japan; PROSPER: Prospective Study of Pravastatin in the Elderly at Risk; RPS: Risk and Prevention Study; SHARP: Study of Heart and Renal Protection;
STABILITY: STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY; STENO-2: STENO-2 Study; TNT: Treating to New Targets; VA Cooperative Study:
Veteran Administration Cooperative Study of Atherosclerosis, Neurology Section; VA-HIT: Veterans Affairs High-Density Lipoprotein Intervention Trial
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[BSR 56.2–100]. Within DSS, 2 of 9 (22 %) enrolled pa-
tients who were in PP at baseline; 2 of 9 (22 %) included
mixed populations whose CV risk was either PP or SP;
and 5 of 9 (56 %) were clinical trials in SP only. Lipid
values at baseline were (mg/dL): 219 (45) [TC]; 140 (41)
[LDL-C]; 41 (5) [HDL-C]; 178 (44) [non-HDL-C]; and
181 (25) [TG] (Table 3). The DSS have investigated the
following interventions over a mean (1SD) duration of
4.4 (1.0) years [BSR: 2.8–5.4 years]: statins (7 trials); and
fibrates (2 trials) (Table 4).
Fourteen other trials, totaling 71,225 patients, dealt ex-
clusively with DM patients, or included a very-high pro-
portion (>45 %) of DM patients at baseline [11, 15–18,
23, 24, 30, 35, 43–46, 67, 71–74, 76, 77, 81], and are de-
scribed below as studies focusing on diabetes (Table 1).
The mean age was 62.6 (8.2) years [BSR 46.0–85.0], and
the proportion of males was 63.0 (8.3) % [BSR 42.5–
74.4]. Mean diabetes duration was 7.5 (4.9) years [BSR
0–18.0], and HbA1c 7.6 (0.7) % [BSR 6.7–8.6] (Table 3).
Among studies focusing on diabetes, 4 of 14 (29 %) en-
rolled patients who were in PP at baseline; 8 of 14
(57 %) included mixed populations whose CV risk was
either PP or SP; and 2 of 14 (14 %) were clinical trials in
SP only. Lipid values at baseline were (mg/dL): 200 (19)
[TC]; 118 (16) [LDL-C]; 46 (6) [HDL-C]; 154 (19) [non-
HDL-C]; and 165 (32) [TG] (Table 3). The studies focus-
ing on diabetes investigated the following interventions
over a mean (1SD) duration of 4.8 (2.7) years [BSR: 1.8–
13.3 years]: statins (5 trials); fibrates (4 trials); n-3 fatty
acids and/or traditional Mediterranean diet (3 trials);
PPAR-γ agonist (2 trials); and PPAR-α/γ agonist (1 trial)
(Table 4).
Among the 33 predominantly non-diabetic studies, a
total of 14,732 and 12,604 events occurred in the com-
parator and treatment arms, respectively. On an annual
basis, this was equivalent to an average rate of occur-
rence for the primary CV outcome of 3.8 (2.4) %/year
[BSR 0.5–11.8] (comparator) and 3.1 (1.8) %/year [BSR
0.3–7.5] (treatment), respectively.
Amongst the 9 DSS, a total of 1,469 and 1,119 events
occurred in the comparator and treatment arms, re-
spectively. On an annual basis, this was equivalent to an
average rate of occurrence for the primary CV outcome
of 6.1 (3.0) %/year [BSR 2.1–10.8] (comparator) and 4.0
(2.1) %/year [BSR 0.7–7.8] (treatment), respectively.
Among the 14 studies focusing on diabetes, a total of
3,713 and 3,552 events occurred in the comparator and
treatment arms, respectively. On an annual basis, this
was equivalent to an average rate of occurrence for the
primary CV outcome of 3.3 (2.5) %/year [BSR 1.1–9.6]
(comparator) and 2.9 (2.4) %/year [BSR 0.8–9.1] (treat-
ment), respectively.
In addition to PO rates, which include de facto CHD,
we also examined CHD rate as a separate outcome
[Table 4 and Fig. 1 left panels]. Rates of CHD were is-
sued for 21 trials and DSS for comparator and treatment
arms, and amounted to [%/year]: 11.1 and 7.2 [4S-DSS];
1.3 and 0.9 [AFCAPS/TexCAPS]; 1.5 and 1.0 [ASCOT-
LLA]; 5.1 and 4.9 [AURORA]; 5.8 and 5.4 [BIP]; 12.0
and 9.3 [CARE-DSS]; 4.9 and 4.5 [CDP (clofibrate)]; 4.9
and 4.1 [CDP (niacin)]; 2.4 and 1.7 [HPS - MRC/BHF];
2.6 and 2.0 [HPS - MRC/BHF-DSS]; 1.4 and 1.3 [HPS2-
THRIVE]; 5.0 and 4.2 [IDEAL]; 2.0 and 2.4 [ILLUMIN-
ATE]; 0.8 and 0.6 [JELIS]; 3.1 and 2.5 [LEADER]; 0.5
and 0.3 [MEGA]; 1.0 and 0.9 [SHARP]; 4.3 and 4.0
[STABILITY]; 1.7 and 1.4 [TNT]; 2.6 and 2.1 [TNT-
DSS]; and 1.9 and 1.7 [VA Cooperative Study] (Fig. 1;
right panels).
The relationship between proportion of diabetic pa-
tients at inclusion and PO or CHD rates was inferred on
Table 2 CV outcomes categories
Total mortality all-cause death A
Composite all CV events (including procedures) B
MACE C
CV death D
Cardiac total CHD/major coronary events E
nonfatal CHD F
cardiac death/fatal CHD G
ACS/ACE H
all MI I
nonfatal MI J
fatal MI K
unstable/hospitalization-requiring AP L
coronary revascularization (PCI or CABG) M
life-threatening arrhytmias N
resuscitation for cardiac arrest O
sudden death P
CHF Q
Coronary imaging angiographic CAD progression/change in
coronary atheroma volume
R
Cerebrovascular all major cerebrovascular events S
all stroke/TIA T
nonfatal stroke U
fatal stroke V
carotid revascularization W
Other composite non-CHD MACE X
Other mortality non-CHD CV death Y
Peripheral any PAD event (including revascularization
and leg amputation)
Z
ACE/ACS: acute coronary event/syndrome; AP angina pectoris; CABG: coronary
artery bypass graft; CAD: coronary artery disease; CHD: coronary heart disease;
CHF: congestive heart failure; CV: cardiovascular; MACE: major adverse
cardiovascular event; MI myocardial infraction; PAD: peripheral arterial disease;
PCI: percutaneous coronary intervention; TIA:transient is chemic attack
(adapted from [91])
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Table 3 Baseline characteristics
Study§ Age
(years)
Males
(%)
Diabetes type & duration
(years)
HbA1c
(%)
TC
(mg/dL)
LDL-C
(mg/dL)
HDL-C
(mg/dL)
Non-HDL-C
(mg/dL)
apoB
(mg/dL)
TG
(mg/dL)
4D 66 54 T2DM 18 6.7 218 125 36 182 ~ 261
4S 59 81 ~ 260 188 46 214 ~ 132
diabetes substudy 60 78 ~ 259 186 43 216 ~ 150
ACCORD-Lipid 62 69 T2DM 10 8.3 175 100 38 137 ~ 164
ADDITION-Europe 60.3 58 T2DM 0 7 214 133 46 168 ~ 146
AFCAPS/TexCAPS 58 85 T1DM; T2DM 221 150 37 184 ~ 158
AIM-HIGH 64 85 ~ 6.7 146 74 35 111 83 168
AleCardio 60.8 73 T2DM 8.6 7.8 152 79 42 110 ~ 152
ALERT 50 66 ~ 247 158 50 197 ~ 195
ALLHAT-LLT 66 51 T2DM 224 146 48 176 ~ 152
Alpha-Omega 69 78 ~ 183 100 50 133 ~ 146
ASCOT-LLA 63 81 ~ 212 131 50 162 ~ 150
diabetes substudy 63.6 76 T2DM 205 128 46 159 ~ 168
ASPEN 61 66 T2DM 8 7.8 194 113 47 147 ~ 147
AURORA 64 62 ~ 176 100 45 131 82 157
diabetes substudy 65 66 ~ 174 97 43 131 ~ 168
BIP 60 91 T2DM 212 148 35 177 ~ 145
CARDS 62 68 T2DM 8 7.9 207 117 54 153 117 173
CARE 59 86 ~ 209 139 39 170 ~ 156
diabetes substudy 61 80 ~ 206 136 38 168 ~ 164
CDP (clofibrate) 100 ~ 252 ~ ~ ~ ~ 183
CDP (niacin) 100 ~ 253 ~ ~ ~ ~ 183
dal-OUTCOMES 60.2 81 ~ 145 76 42 103 81 134
DIS 46 56 T2DM 0 218 ~ ~ ~ ~ 157
FIELD 62 63 T2DM 5 6.9 195 119 43 152 97 173
GISSI-Prevenzione 60 86 T2DM (79 %)
T1DM (21 %)
229 152 46 183 ~ 166
GREACE 79 ~ 264 193 39 225 ~ 159
diabetes substudy 55 56 T2DM (92 %)
T1DM (8 %)
10.5 7.5 271 189 35 236 ~ 221
HATS 53 87 ~ 200 128 30 170 119 219
HHS 47 100 ~ 270 189 47 223 ~ 175
diabetes substudy 49 100 T2DM 4.5 292 200 46 246 ~ 214
HPS - MRC/BHF 75 ~ 228 131 41 187 114 186
diabetes substudy 62.1 70 T2DM (90 %)
T1DM (10 %)
27 7 220 124 41 179 110 204
HPS2-THRIVE 64.9 82.7 ~ 128 63 44 84 68 127
IDEAL 62 81 ~ 197 122 46 151 119 151
ILLUMINATE 61.3 77.8 T2DM 157 80 49 108 73 127
JELIS 61 31.4 ~ 275 181 59 216 ~ 153
LEADER 68 100 ~ 218 131 46 172 ~ 213
LIPID 62 83 ~ 218 150 36 182 133 142
LIPS 60 84 T2DM; T1DM 200 131 38 162 ~ 160
MEGA 58.3 32 ~ 242 157 58 184 ~ 128
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the basis of the comparator and treatment arms data
from the 33 predominantly non-diabetic studies, includ-
ing where appropriate the rates for the corresponding
DSS, ie 259,151 patients. Both for PO and CHD, there
was a highly significant linear relationship between the
proportion of diabetics enrolled and events rates, both
in comparator arms (p = 0.0128 [PO] and p = 0.0094
[CHD]; Fig. 1; upper panels) and active arms (p = 0.0470
[PO] and p = 0.0272 [CHD]; Fig. 1; lower panels). When
comparing the slopes of the equations between PO and
the proportion of diabetes at baseline in the comparator
arm of studies published < 2005 and from 2005 to 2014,
they rose from 0.0129 to 0.0162, ie a relative increase of
26 % (not shown). Such relationships were more pro-
nounced as regards CHD events, exhibiting steeper gra-
dients than those of PO rates, with slope coefficients
higher by a relative 78 % [comparator arms] and 110 %
[treatment arms]. Vis-à-vis the comparator arms, the
slopes of the relationships between proportions of dia-
betics and events rates in the treatment arms of the
same studies were attenuated, by a relative 45 % [PO
rates] and 34 % [CHD events] (Fig. 1; lower panels).
Computing occurrence rates of PO and CHD in the
comparator arms showed that the proportion of dia-
betics at inclusion predicted PO rates ranging from
3.12 %/year (no diabetic included) to 6.11 %/year (all pa-
tients diabetic). Predicted CHD rates depending on base-
line diabetes prevalence ranged from 1.54 %/year (no
diabetic included) to 6.85 %/year (all patients diabetic).
This implies that a cohort exclusively composed of dia-
betic patients would present a PO rate already increased
by an absolute 3 %/year due to the mere fact of being
diabetic at baseline. Such an out-of-hand absolute in-
crease in events rate due to the diabetic state would fur-
ther increase to 5.3 %/year when it comes to the risk of
incident CHD (Fig. 1; upper panels).
By relating incidence rates of PO and CHD in the treat-
ment arms, it appears that the proportion of diabetics at
inclusion predicts PO rates ranging from 2.65 %/year (no
diabetic included) to 4.31 %/year (all patients diabetic).
Predicted CHD rates based on diabetes prevalence ranged
from 1.64 %/year (no diabetic included) to 5.13 %/year (all
patients diabetic). It follows that a cohort exclusively com-
posed of diabetic patients would present an on-treatment
PO rate increased by an absolute 1.7 %/year solely due to
the presence of DM at baseline. Such an absolute increase
in events rate due to diabetes would further increase to
3.5 %/year for incident CHD risk (Fig. 1; lower panels).
The comparison of these equations linking the propor-
tion of diabetics and outcome rates in comparator vs.
treatment arms allows for determining whether being
diabetic (apart from the observation that it increases the
absolute rate of occurrence of CV events) is associated
with an idiosyncratic on-treatment clinical response. As
for PO and CHD, diabetic patients were characterized by
a clinical response that was better than that calculated for
a non-diabetic population that would have been subject to
the same therapeutic interventions. Thus, residual CV risk
Table 3 Baseline characteristics (Continued)
ORIGIN 63.5 65 T2DM 5.4 189 112 46 143 ~ 142
PERFORM 67.2 62.5 ~ ~ 93 ~ ~
Post-CABG 61.7 92 ~ 226 156 39 187 ~ 158
PREDIMED 67 43 ~ 219 143 53 172 102 142
PROACTIVE 61.8 66 T2DM 9.5 8.1 199 114 45 154 ~ 198
PROFIT-J 85 65 T2DM 11.3 7.4 198 115 55 144 ~ 141
PROSPER 75 48 ~ 220 147 50 170 ~ 133
RPS 63.9 61.5 ~ 6.7 216 132 51 165 ~ 150
SHARP 62 63 ~ 189 107 43 146 92 205
STABILITY 65 81 ~ ~ 80 45 ~
STENO-2 54.9 74 T2DM 5.8 8.6 210 133 40 170 ~ 159
TNT 61 81 ~ 175 97 47 128 111 151
diabetes substudy 63 73 ~ 8.5 7.4 175 96 45 130 113 171
VA Cooperative Study 55 100 ~ 244 ~ ~ ~ ~ ~
VA-HIT 64 100 ~ 175 111 32 143 96 161
diabetes substudy 65 ~ 172 108 31 141 ~ 166
mean 61.7 74 7.5 7.49 209 126 44 161 99 162
standard deviation 6.4 17 4.9 0.68 34 32 7 32 19 27
§: see legend to Table 1 for study acronyms definition; apoB: apolipoprotein B100; C: cholesterol; HbA1c: glycated haemoglobin A1c; HDL: high-density lipoprotein;
LDL: low-density lipoprotein; T1DM and T2DM: type 1 and type 2 diabetes mellitus; TG: triglycerides
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Table 4 Primary CV outcome rates in the active (treatment) and control (comparator/placebo) arms
Study§ Intervention Primary; secondary
CV outcomes§§
Events (n)
treatment
Events (%)
treatment
Rate
(%.year-1)
treatment
Events (n)
control
Events (%)
control
Rate (%.year-1)
control
HR 95 % CI
for HR
P
4D statin C; D + J 226 36.5 9.13 243 38.2 9.55 0.96 0.77-1.1 0.37
4S statin A 182 8.2 1.52 256 11.5 2.13 0.71 0.58-0.85 0.0003
diabetes
substudy
statin A 15 14.3 2.65 24 24.7 4.58 0.58 NR 0.087
ACCORD-Lipid fibrate C; J + D 291 10.5 2.24 310 11.3 2.40 0.93 0.79-1.08 0.32
ADDITION-Europe statin/other B; D + J + M + Z 121 7.2 1.36 117 8.5 1.60 0.85 0.65-1.05 0.12
AFCAPS/TexCAPS statin C; E 116 3.5 0.68 183 5.5 1.07 0.63 0.50-0.79 <0.001
AIM-HIGH niacin C; G + J + H +M 282 16.4 5.47 274 16.2 5.39 1.02 0.87-1.21 0.8
AleCardio PPAR-α/γ C; D + J 344 9.5 4.76 360 10.0 4.99 0.95 0.83-1.11 0.57
ALERT statin C; G + J + M 112 10.7 2.09 134 12.7 2.50 0.84 0.64-1.06 0.14
ALLHAT-LLT statin A 631 12.2 2.54 641 12.4 2.58 0.99 0.89-1.11 0.88
Alpha-Omega n-3 fatty
acids
B 336 14.0 4.11 335 13.8 4.05 1.02 0.87-1.17 0.93
ASCOT-LLA statin J + G 100 1.9 0.59 154 3.0 0.91 0.65 0.50-0.83 0.0005
diabetes
substudy
statin B 116 9.2 2.79 151 11.9 3.59 0.78 0.61-0.98 0.04
ASPEN statin C; D + J + M + O
+ L
166 13.7 3.43 180 15.0 3.75 0.91 0.73-1.12 0.34
AURORA statin C; J + D 396 28.5 7.50 408 29.5 7.76 0.97 0.84-1.11 0.59
diabetes
substudy
statin C; G + J 85 21.9 7.82 104 30.3 10.83 0.72 0.51-0.90 0.008
BIP fibrate C; K + J + P 211 13.6 2.20 232 15.0 2.43 0.91 NR 0.26
CARDS statin C; H + M + T 83 5.8 1.49 127 9.0 2.31 0.65 0.48-0.83 0.001
CARE statin G + J 212 10.2 2.04 274 13.2 2.64 0.77 0.09-0.36 0.003
diabetes
substudy
statin G + J + M 81 28.7 5.74 112 36.8 7.37 0.78 NR <0.0001
CDP (clofibrate) fibrate A 281 25.5 4.11 709 25.4 4.10 1.00 NR NR
CDP (niacin) niacin A 273 24.4 3.93 709 25.4 4.10 0.96 0.85-1.08 NR
dal-OUTCOMES CETP
inhibitor
C; G + J + L + O 656 8.3 3.20 633 8.0 3.09 1.04 0.93-1.16 0.52
DIS fibrate E 32 8.4 1.69 31 8.1 1.62 1.04 NR NR
FIELD fibrate C; B + D + I + M 256 5.2 1.05 288 5.9 1.18 0.89 0.75-1.05 0.16
GISSI-Prevenzione statin C; A + I 120 5.6 2.77 136 6.4 3.15 0.88 0.71-1.15 0.41
GREACE statin C; A + J + L + Q +
M
112 12.7 4.24 180 25.0 8.33 0.51 <0.0001
diabetes
substudy
statin C; A + J + L + Q +
M
20 12.4 4.14 46 30.3 10.09 0.41 NR <0.0001
HATS statin +
niacin§§§
R + B; D + J + M 7 9.6 3.20 12 35.3 11.76 0.27 NR 0.02
HHS fibrate C; K + J + G 56 2.7 0.55 84 4.1 0.83 0.66 0.08-0.53 <0.02
diabetes
substudy
fibrate C; K + J + G 2 3.4 0.68 8 10.5 2.11 0.32 NR 0.19
HPS - MRC/BHF statin C; A + G 1328 12.9 2.59 1507 14.7 2.94 0.88 0.81-0.94 0.0003
diabetes
substudy
statin E + B 601 20.2 4.20 748 25.1 5.22 0.81 0.19-0.30 <0.0001
HPS2-THRIVE niacin C; G +M 1696 13.2 3.39 1758 13.7 3.51 0.96 0.90-1.03 0.29
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persisting after treatment was further reduced in case of
diabetes, in a relative proportion of 14.4 % [PO] and
31.2 % [CHD], respectively (Fig. 1; upper and lower
panels).
Discussion
This meta-analysis shows that the presence of diabetics
in a lipid-modifying trial is a determinant of CV events
rate, the impact of which can be accurately assessed
once known the proportion of diabetics enrolled, regard-
less of the CV risk category at baseline. Thus, the linear
equations derived from this meta-analysis can be used to
determine the absolute and relative enhancement of CV
risk related to the inclusion of diabetics in a trial. Con-
versely, these algorithms can be used to estimate the
proportion of diabetics to be included when designing a
prospective study, in order to achieve a given number of
CV events.
Major guidelines recognize a higher risk of CHD in
DM patients, even in situations of primary prevention,
as compared to non-diabetic subjects. The events rates
in the comparator arms of randomized controlled trials
and the meta-analyses of key statin trials show that
CHD risk from hypercholesterolemia in non-diabetic
Table 4 Primary CV outcome rates in the active (treatment) and control (comparator/placebo) arms (Continued)
IDEAL statin C; G + J + O 411 9.3 1.93 463 10.4 2.17 0.89 0.78-1.01 0.07
ILLUMINATE CETP
inhibitor
C; G + J + L 464 6.2 6.16 373 5.0 4.95 1.24 1.09-1.44 0.001
JELIS n-3 fatty
acids
E; P; I; L; M; A 262 2.8 0.61 324 3.5 0.76 0.81 0.69-0.95 0.01
LEADER fibrate E 150 19.2 4.95 160 20.4 5.20 0.95 0.76-1.21 0.72
LIPID statin G 287 6.4 1.04 373 8.3 1.36 0.77 0.12-0.35 <0.001
LIPS statin C; G + J + M 181 21.4 5.50 222 26.7 6.83 0.80 0.64-0.95 0.01
MEGA statin C; I + L + M + P 66 1.7 0.32 101 2.5 0.48 0.67 0.49-0.91 0.01
ORIGIN n-3 fatty
acids
D; D + J + U; A; I;
T; M +W; Q; L; Z
574 9.1 1.47 581 9.3 1.50 0.98 0.87-1.10 0.72
PERFORM antiplatelet D; I 1091 11.4 4.83 1062 11.1 4.71 1.03 0.94-1.12 NS
Post-CABG statin C; D + J + M 207 30.6 4.08 271 40.1 5.35 0.76 NR 0.04
PREDIMED TMD C; D + I 179 3.6 0.80 109 4.4 1.12 0.71
PROACTIVE glitazone C; A + J + H +M 514 19.7 6.80 572 21.7 7.49 0.91 0.80-1.02 0.1
PROFIT-J glitazone C; A + J 9 3.8 2.09 10 4.0 2.20 0.95 0.427-
2.593
0.91
PROSPER statin C; G + J 408 14.1 4.41 473 16.2 5.07 0.87 0.74-0.97 0.01
RPS n-3 fatty
acids
D 733 11.7 2.35 745 11.9 2.38 0.99 0.88-1.08 0.64
SHARP statin/
ezetimibe
C; J + G +M 526 11.3 2.31 619 13.4 2.73 0.84 0.74-0.94 0.0021
STABILITY Lp-PLA2-
inhibitor
C; D + J + U 769 9.7 2.62 819 10.4 2.80 0.94 0.85-1.03 0.2
STENO-2 statin/
fibrate
A 24 30.0 2.26 40 50.0 3.76 0.60 0.32-0.89 0.02
TNT statin C; G + J + O + T 434 8.7 1.77 548 10.9 2.23 0.79 0.69-0.89 <0.001
diabetes
substudy
statin C; G + J + O + T 103 13.7 2.79 135 18.0 3.68 0.76 0.58-0.97 0.026
VA Cooperative
Study
fibrate A + B 22 8.2 4.56 30 11.4 6.31 0.72 0.43-1.22 NR
VA-HIT fibrate C; J + G 219 17.3 3.40 275 21.7 4.26 0.80 0.07-0.35 0.006
diabetes
substudy
fibrate C; J + G 96 25.5 4.99 141 36.0 7.05 0.71 0.53-0.88 0.004
Total (n) 16156 18445
Mean 12.2 3.0 14.8 3.6 0.85
§: see legend to Table 1 for study acronyms definition; §§: see Table 2 for CV outcomes definition; §§§: ±antioxidants; CETP: cholesteryl ester transfer protein; CI:
confidence interval; CV: cardiovascular; HR: hazard ratio; LpPLA2: lipoprotein-associated phospholipase A2; NR: not reported; NS: non significant; PPAR: peroxisome
proliferator-activated receptor; TMD: traditional Mediterranean diet
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patients is proportional to baseline LDL-C level. This is
also the case for type 2 DM patients, with the add-
itional aggravating fact that this linear relationship was
shifted upward compared to non-diabetics. This under-
lies current recommendations for effective lowering of
LDL-C as the major modifiable lipid risk factor for
CHD in diabetic patients.
It should be noted that mean PO rate in studies focus-
ing on diabetes was considerably lower (-46 %) than the
risk that would be determined for diabetics if included,
y = 0.0299 x + 3.12
R² = 0.1419
p = 0.0128
0
2
4
6
8
10
12
0 20 40 60 80 100
y = 0.0166 x + 2.65
R² = 0.0935
p = 0.0470
0
2
4
6
8
10
12
0 20 40 60 80 100
diabetic patients at inclusion (%)
P
ri
m
ar
y 
o
u
tc
o
m
e 
ra
te
  
in
 c
o
m
p
ar
at
o
r 
ar
m
 (
%
 /
 y
ea
r)
 
P
ri
m
ar
y 
o
u
tc
o
m
e 
ra
te
  
in
 t
re
at
m
en
t 
 a
rm
 (
%
 /
 y
ea
r)
 y = 0.0349 x + 1.64
R² = 0.2304
p = 0.0272
0
2
4
6
8
10
12
0 20 40 60 80 100
y = 0.0531 x + 1.54
R² = 0.3092
p = 0.0094
0
2
4
6
8
10
12
0 20 40 60 80 100
diabetic patients at inclusion (%)
C
H
D
 e
ve
n
ts
  
in
 c
o
m
p
ar
at
o
r 
ar
m
 (
%
 / 
ye
ar
) 
C
H
D
 e
ve
n
ts
  
in
 t
re
at
m
en
t 
 a
rm
 (
%
 / 
ye
ar
) 
Fig. 1 Relationship between proportion of diabetic patients at inclusion (%) and primary outcome rates (%/year; left panels) or total coronary heart
disease (CHD) events (%/year; right panels) in comparator arms (upper panels) and in treatment arms (lower panels) of 33 landmark trials that included a
substantial minority of diabetics (ranging from 2 % to 44 %), representing a total of 259,151 patients. The graphs are based on data from the following
trials: 4S; AFCAPS/TexCAPS; AIM-HIGH; ALERT; ALLHAT-LLT; Alpha-Omega; ASCOT-LLA; AURORA; BIP; CARE; CDP; dal-OUTCOMES; GISSI-Prevenzione; GREACE;
HATS; HHS; HPS-MRC/BHF; HPS2-THRIVE; IDEAL; ILLUMINATE; JELIS; LEADER; LIPID; LIPS; MEGA; PERFORM; Post-CABG; PROSPER; SHARP; STABILITY; TNT; VA
Cooperative Study; and VA-HIT. The open diamonds represent primary outcome rates and CHD events from the following diabetes substudies: 4S;
ASCOT-LLA; AURORA; CARE; GREACE; HHS; HPS-MRC/BHF; TNT; and VA-HIT. See Table 1 for acronyms definition and trials’ references, and Table 2 and
Table 4 for primary outcomes classification and description
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as a subgroup, in a clinical trial not focusing on diabetes.
This follows from the fact that studies focusing on dia-
betes had a lower CV risk at inclusion, as well as lesser
PO or CHD events during the study. As a result, the im-
pact of DM on CV events must be qualified according
to whether it is evaluated from diabetic subgroups of co-
horts followed in cardiology (mostly in a macrovascular
setting), or whether it is obtained in patients from clinical
trials focusing on nutrition or diabetes (usually dealing
with glycemic control or microvascular risk reduction). In
addition, variation in residual risk related to T2DM in key
trials may result from inhomogeneity in inclusion criteria;
varying baseline CV risk; individual differences in diabetes
duration or severity; and heterogeneous RFs exposure
among diabetics.
As opposed to what occurs in microvessels, and unlike a
widely held view about it, residual risk targeting large ves-
sels is related to a limited extent only by hyperglycaemia in
(pre)diabetes states. Rather, the accrued macrovascular risk
is associated with the common form of T2DM (that is to
say the one that expresses a MetS phenotype, including
insulin resistance and hyperinsulinemia). The common
pathogenic factors underlying the observed association be-
tween hyperglycemia and CHD are involved either (i) at the
onset of diabetes (promoting B-cell decompensation or al-
tering one or two variable(s) of the hyperbolic product be-
tween insulin secretion and insulin sensitivity), and/or (ii)
because they embody cardiometabolic comorbidities that
increase the macrovascular risk regardless of glucose levels.
It should be noted that the slopes of the relationships
between CV events and percentage of included diabetics
were less marked when it came to comparing PO vs. CHD
events rates, both in comparator and treatment arms, on
one hand, or when it came to comparing PO or CHD
events rates in treated arms vs. comparator arms, on the
other hand. These observations suggest (i) that the pres-
ence of diabetes at baseline has less adverse effect on the
occurrence of certain constituents of the PO, such as all-
cause deaths or coronary revascularization; and (ii) that
diabetic patients derive more benefits from the different
treatment approaches studied than non-diabetic patients
as regards the occurrence of macrovascular events [91]. In
this meta-analysis, we have not distinguished between
studies on the basis of pharmacological or nutritional
interventions, since we based our findings on patients
from comparator arms, usually receiving a placebo or
standard care. When comparing less recent (published
<2005) and more contemporary studies (published
≥2005), a decrease in absolute and relative events rates
was observed (-28 % and -1 % respectively), suggestive
of a reduction in exposure to CV RFs over time and/or
of improved overall CV management. Such changes
were however not significant and further, diabetic patients
benefited less from this trend, reducing the absolute and
relative rates by only -14 % and -0.7 %. It seemed therefore
appropriate to include all studies in this analysis regardless
of publication year.
It is noteworthy that the increased risk of CV events
due to the presence of a subgroup of diabetics had a
pretty similar slope, whatever the CV risk category at
baseline. It follows that the excess CV risk associated
with the inclusion of people with diabetes in a lipid-
modifying trial is relatively independent of study design,
expanding the applicability of equations derived from
this meta-analysis. There exists a positive relationship
between biomarkers and occurrence of CV events [92];
our meta-analysis suggests that documenting the fre-
quency of enlisted T2DM patients can also be used as
surrogate biomarker predicting a non-modifiable com-
ponent of residual CV risk. Considering that our analysis
focused on populations enrolled in the comparator arms
of mostly LMT studies, it would be interesting to deter-
mine the impact on residual risk arising from enlistment
of diabetics in clinical trials testing several interventions
in primary care [93].
This study has several limitations. Firstly, the risk esti-
mates attributed to DM were not adjusted for age or other
CV RFs comorbid to T2DM and, as in all systematic col-
lection of published data, there is always a potential bias
related to publications [94]. Secondly, the adequacy of
these equations to predict CV outcomes has not been in-
dependently validated in a prospective context. Thirdly,
for reasons related to the design and reporting of individ-
ual studies, it was not feasible to derive specific equations
applicable to T1DM vs. T2DM subgroups, or to newly-
diagnosed vs. long-standing T2DM patients [95]. We were
not able to analyze the potential influence of glycaemic
control in diabetic subgroups at baseline, due to the low
reporting rate of HbA1c values [96]. Finally, we did not
examine, for reasons of brevity, the relationship between
diabetes prevalence and non-CHD outcomes, such as HF,
which will require dedicated meta-analyses [97].
Conclusion
This study attempted to quantify the impact of diabetes
on the occurrence of CV events during a lipid-modifying
trial, based on the proportion of known diabetics in-
cluded. The component of absolute and relative residual
CV risk associated with diabetes can be measured from
linear equations relating diabetes prevalence to primary
outcomes or CHD rates. Such calculations may help
clinical study designers when selecting inclusion criteria;
cohort size; and planned diabetics’ enrollment, so as to
achieve sufficient CV events over time.
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